Table 1.
STAPRA study baseline characteristics
| Atorvastatin n=31 | Placebo n=31 | |
| Age, mean (SD) | 49 (8) | 46 (11) |
| Female sex, n (%) | 21 (68) | 25 (81) |
| Current smoker, n (%) | 11 (36) | 13 (42) |
| Current alcohol use, n (%) | 16 (52) | 23 (74) |
| BMI, mean (SD) | 25.9 (5.2) | 27.0 (5.7) |
| RF positive, n (%) | 23 (74) | 17 (55) |
| RF level, median (IQR) | 19 (42) | 10 (44) |
| ACPA positive, n (%) | 31 (100) | 31 (100) |
| ACPA level, median (IQR) | 304 (551) | 146 (304) |
| CRP, median (IQR) | 2 (1.8) | 2 (3.8) |
| ESR, median (IQR) | 10 (14) | 7 (7) |
| VAS global disease activity, median (IQR) | 32 (55) | 29 (55) |
| TJC, median (IQR) | 0 (2) | 1 (2) |
ACPA, anticitrullinated protein antibody; BMI, body mass index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; STAPRA, STAtins to Prevent Rheumatoid Arthritis; TJC, tender joint count; VAS, Visual Analogue Scale.